Form 4: Beta Bionics Director Acquires Stock Options

A Beta Bionics director, Christy Jones, has acquired stock options for a total of 66,904 shares of common stock.

Summary

• Christy Jones, a director at Beta Bionics, has reported the acquisition of stock options.
• These options are for a total of 66,904 shares of common stock.
• The options were granted on January 31, 2025, at an exercise price of $7.51 per share.
• The options vest over different periods, with some vesting monthly from April 2021, July 2021 and July 2022.
• The options expire on December 7, 2031 and July 26, 2032.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally a positive sign of alignment between management and shareholders. It is not a major event, but it is a positive indicator.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for directors and officers of publicly traded companies when they acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across publicly traded companies as part of their compensation and incentive programs.
• The vesting schedules of 36 and 48 months are also typical for such grants, aligning the director's interests with the long-term performance of the company.
• The exercise price of $7.51 is a key detail, as it represents the price at which the director can purchase the shares, and is usually set at or above the market price at the time of grant.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, insider trading, beneficial ownership, Beta Bionics, BBNX